95 related articles for article (PubMed ID: 36016193)
1. Intradermal Immunization of SARS-CoV-2 Original Strain Trimeric Spike Protein Associated to CpG and AddaS03 Adjuvants, but Not MPL, Provide Strong Humoral and Cellular Response in Mice.
Firmino-Cruz L; Dos-Santos JS; da Fonseca-Martins AM; Oliveira-Maciel D; Guadagnini-Perez G; Roncaglia-Pereira VA; Dumard CH; Guedes-da-Silva FH; Vicente Santos AC; Alvim RGF; Lima TM; Marsili FF; Abreu DPB; Rossi-Bergmann B; Vale AM; Filardy AD; Silva JL; de Oliveira AC; Gomes AMO; de Matos Guedes HL
Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016193
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum.
Dos-Santos JS; Firmino-Cruz L; da Fonseca-Martins AM; Oliveira-Maciel D; Perez GG; Roncaglia-Pereira VA; Dumard CH; Guedes-da-Silva FH; Santos ACV; Leandro MDS; Ferreira JRM; Guimarães-Pinto K; Conde L; Rodrigues DAS; Silva MVM; Alvim RGF; Lima TM; Marsili FF; Abreu DPB; Ferreira OC; Mohana Borges RDS; Tanuri A; Souza TML; Rossi-Bergmann B; Vale AM; Silva JL; de Oliveira AC; Filardy AD; Gomes AMO; de Matos Guedes HL
Front Immunol; 2022; 13():884760. PubMed ID: 35844561
[TBL] [Abstract][Full Text] [Related]
3. A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice.
Coria LM; Saposnik LM; Pueblas Castro C; Castro EF; Bruno LA; Stone WB; Pérez PS; Darriba ML; Chemes LB; Alcain J; Mazzitelli I; Varese A; Salvatori M; Auguste AJ; Álvarez DE; Pasquevich KA; Cassataro J
Front Immunol; 2022; 13():844837. PubMed ID: 35296091
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine.
Atalis A; Keenum MC; Pandey B; Beach A; Pradhan P; Vantucci C; Jain R; Hosten J; Smith C; Kramer L; Jimenez A; Ochoa MA; Frey D; Roy K
bioRxiv; 2022 Feb; ():. PubMed ID: 35132413
[TBL] [Abstract][Full Text] [Related]
5. The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice.
Xu K; Li J; Lu X; Ge X; Wang K; Wang J; Qiao Z; Quan Y; Li C
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250873
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
7. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
8. Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
Liu H; Zhou C; An J; Song Y; Yu P; Li J; Gu C; Hu D; Jiang Y; Zhang L; Huang C; Zhang C; Yang Y; Zhu Q; Wang D; Liu Y; Miao C; Cao X; Ding L; Zhu Y; Zhu H; Bao L; Zhou L; Yan H; Fan J; Xu J; Hu Z; Xie Y; Liu J; Liu G
Vaccine; 2021 Nov; 39(48):7001-7011. PubMed ID: 34750014
[TBL] [Abstract][Full Text] [Related]
9. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
Steinbuck MP; Seenappa LM; Jakubowski A; McNeil LK; Haqq CM; DeMuth PC
Sci Adv; 2021 Feb; 7(6):. PubMed ID: 33547083
[TBL] [Abstract][Full Text] [Related]
10. Adjuvanted-SARS-CoV-2 Spike Protein-Based Microparticulate Vaccine Delivered by Dissolving Microneedles Induces Humoral, Mucosal, and Cellular Immune Responses in Mice.
Patil S; Vijayanand S; Menon I; Gomes KB; Kale A; Bagwe P; Yacoub S; Uddin MN; D'Souza MJ
Pharmaceuticals (Basel); 2023 Aug; 16(8):. PubMed ID: 37631046
[TBL] [Abstract][Full Text] [Related]
11. HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.
Apostólico Jde S; Boscardin SB; Yamamoto MM; de Oliveira-Filho JN; Kalil J; Cunha-Neto E; Rosa DS
PLoS One; 2016; 11(1):e0145637. PubMed ID: 26727218
[TBL] [Abstract][Full Text] [Related]
12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting protective immunity against H7N9 infection is induced by intramuscular or CpG-adjuvanted intranasal immunization with the split H7N9 vaccine.
Zhou Y; Li S; Bi S; Li N; Bi Y; Liu W; Wang B
Int Immunopharmacol; 2020 Jan; 78():106013. PubMed ID: 31806571
[TBL] [Abstract][Full Text] [Related]
14. Distinct Effects of Monophosphoryl Lipid A, Oligodeoxynucleotide CpG, and Combination Adjuvants on Modulating Innate and Adaptive Immune Responses to Influenza Vaccination.
Ko EJ; Lee YT; Lee Y; Kim KH; Kang SM
Immune Netw; 2017 Oct; 17(5):326-342. PubMed ID: 29093654
[TBL] [Abstract][Full Text] [Related]
15. Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates.
S Arunachalam P; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Roltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Doyle-Meyer L; Bohm RB; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O Hagan DT; Most RV; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar M; King NP; Veesler D; Pulendran B
bioRxiv; 2021 Feb; ():. PubMed ID: 33594366
[TBL] [Abstract][Full Text] [Related]
16. Codelivery of adjuvants at the primary immunization site is essential for evoking a robust immune response to neoglycoconjugates.
Safari D; Dekker HA; Rijkers G; Snippe H
Vaccine; 2011 Jan; 29(4):849-54. PubMed ID: 21111776
[TBL] [Abstract][Full Text] [Related]
17. Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants.
Masuda A; Lee JM; Miyata T; Mon H; Sato K; Oyama K; Sakurai Y; Yasuda J; Takahashi D; Ueda T; Kato Y; Nishida M; Karasaki N; Kakino K; Ebihara T; Nagasato T; Hino M; Nakashima A; Suzuki K; Tonooka Y; Tanaka M; Moriyama T; Nakatake H; Fujita R; Kusakabe T
Front Immunol; 2021; 12():803647. PubMed ID: 35095889
[TBL] [Abstract][Full Text] [Related]
18. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
19. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.
Khodai T; Chappell D; Christy C; Cockle P; Eyles J; Hammond D; Gore K; McCluskie MJ; Evans DM; Lang S; Loudon PT; Townend T; Wright P; West K; Bright H
Clin Vaccine Immunol; 2011 Oct; 18(10):1702-9. PubMed ID: 21852545
[TBL] [Abstract][Full Text] [Related]
20. CpG 684: an effective adjuvant for the inactivated COVID-19 vaccine in mice.
Liu J; Cang T; Jiang C; Li K; Liu S; Wang H; Wang M; Chen Y; Shao Y; Liu J
Future Virol; 2023 May; 18(7):403-410. PubMed ID: 38051998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
